CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Rare Diseases (230)
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease utilizing expertise in bile acid chemistry. The company's product candidates have the potential t...Show all
Company (IPO / Went public)
Phone: 646-747-1000
18 Desbrosses Street
New York, 10013
New York, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Intercept Pharmaceuticals | $121M | Apr 5, 2018 |
| Intarcia Therapeutics | $1586.9M | Mar 12, 2019 |
| Glaukos | $232M | Nov 1, 2017 |
| See all 42 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Preparation and uses of obeticholic acid | Dec 22, 2015 | May 29, 2018 | Patent |
| Process for preparing bile acid derivatives | Oct 25, 2013 | Oct 03, 2017 | Patent |
| Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions | Jun 18, 2015 | Sep 19, 2017 | Patent |
| Steroids as agonists for fxr | Feb 05, 2016 | Aug 15, 2017 | Patent |
| Preparation and uses of obeticholic acid | Nov 20, 2015 | Aug 15, 2017 | Patent |
